<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-C
REPORT BY ISSUER OF SECURITIES QUOTED ON NASDAQ
INTERDEALER QUOTATION SYSTEM
FILED PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934 AND RULE 13a-17
OR 15d-17 THEREUNDER
GelTex Pharmaceuticals, Inc.
- --------------------------------------------------------------------------------
(Exact name of issuer as specified in charter)
303 Bear Hill Road, Waltham, Massachusetts 02154
- --------------------------------------------------------------------------------
(Address of principal executive offices)
Issuer's telephone number, including area code (617) 290-5888
--------------------------------
I. CHANGE IN NUMBER OF SHARES OUTSTANDING
Indicate any change (increase or decrease) of five percent or more in the number
of shares outstanding:
1. Title of security Common Stock, $.01 par value per share
------------------------------------------------------
2. Number of shares outstanding before the change 10,612,317
-------------------------
3. Number of shares outstanding after the change 13,487,317
--------------------------
4. Effective date of change May 7, 1996 and May 14, 1996
----------------------------------------------
5. Method of change: Specify method (such as merger, acquisition,
exchange, distribution, stock split, reverse split, acquisition
of stock for treasury, etc.)
Public offering
- --------------------------------------------------------------------------------
Give brief description of transaction Sale of 2,500,000 shares of Common
---------------------------------------
Stock at $22.75 per share on May 7, 1996 and 375,000 shares at the same price
- --------------------------------------------------------------------------------
on May 14, 1996
- ---------------
II. CHANGE IN NAME OF ISSUER
1. Name prior to change
-----------------------------------------------
2. Name after change
-------------------------------------------------
3. Effective date of charter amendment changing name
------------------
4. Date of shareholder approval of change, if required
---------------
Date: May 14, 1996 /s/ Mark Skaletsky
-------------------------------
Mark Skaletsky
President and Chief Executive Officer
